SIGLEC7 and breast carcinoma: Depletion of CD169+ TAMs was effective in reducing tumor burdens and metastasis in mouse models of breast cancer, whereas targeting of SIGLEC7 and SIGLEC9 led to a significant reduction in tumor burdens in transgenic mice expressing the human transgenes for SIGLEC7 and SIGLEC9 but lacking expression of the murine homolog Siglec-E that were transplanted with murine B16 and B16-FUT3 lung cancer cells (257).